Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)